Journal of autoimmunityHumansLupus ErythematosusSystemicFemaleAdult
Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study.
Yiyang Wang, Shaoying Yang, Ye Yu, Peng Xia, Cuiwei Xie, Chunyan Zhang, Liangjing Lu
Published: 202510.1016/j.jaut.2025.103489
Abstract
BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy has emerged as a transformative treatment in autoimmune diseases. Relmacabtagene autoleucel (relma-cel) is an autologous, CD19-directed CAR-T cell product developed with a commercial-ready pr…
Preview only. Read the full abstract at the source